13F Holdings
中文EN

ACUT Accustem Sciences Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1850767 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-7.2%
TTM EPS YoY8.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-102.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets356.4%
Debt / equity—
Current ratio0.02x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-27.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$281,014$138,324$139,663$266,933$73,335
SG&A expense$1.48M$1.37M$1.91M$3.48M$597,279
Operating income-$1.76M-$1.51M-$2.05M-$3.75M-$670,614
Pretax income-$1.76M-$1.51M-$2.05M-$3.75M-$670,614
Net income-$1.76M-$1.51M-$2.05M-$3.75M-$670,614
EBITDA-$1.76M-$1.50M-$2.05M-$3.74M—
EPS (basic)-0.12-0.13-0.18-0.34-0.07
EPS (diluted)-0.12-0.13-0.18-0.34—
Weighted avg. shares (diluted)15.23M11.44M11.35M11.02M—
Balance sheet
Cash & equivalents$13,929$5,046$21,481$733,978—
Current assets$49,446$50,433$129,849$932,011$1.35M
PP&E, net—$418$4,048$7,678—
Total assets$1.55M$50,851$133,897$939,689$1.35M
Current liabilities$4.95M$3.36M$2.25M$1.08M$702,700
Total liabilities$4.95M$3.36M$2.25M$1.08M$702,700
Shareholders' equity-$3.40M-$3.31M-$2.11M-$139,550$650,673
Shares outstanding16.07M12.10M11.35M11.35M10.00M
Cash flow statement
Operating cash flow-$850,389-$664,066-$1.62M-$1.81M—
Capital expenditure———$10,999—
Free cash flow———-$1.82M—
Investing cash flow———-$10,999—
Financing cash flow$859,271$647,632$903,146$2.55M—
Depreciation & amortization$418$3,630$3,630$3,321—
Stock-based compensation$88,695$69,718$78,634$133,889$21,260

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.